

## Medicine and Rheumatology

### 1. Staffs and Students (April, 2009)

Professor	Nobuyuki MIYASAKA Masayoshi HARIGAI	
Associate Professor	Hitoshi KOHSAKA, Ryuji KOIKE,	Tetsuo KUBOTA, Toshihiro NANKI
Junior Associate Professor	Kazuki TAKADA,	Hideyuki IWAI
Assistant Professor	Shinya HIRATA, Michi TANAKA,	Fumitaka MIZOGUCHI, Yoshinori NONOMURA
Research Nurse	Shoko KAWASE	
Graduate Student	Akito TAKAMURA, Kayoko KANEKO, Naoko OKIYAMA, Yoshishige MIYABE, Akiko SUZUKI	Kaori WATANABE, Masayasu TOYOMOTO, Ryoko SAKAI, Chie MIYABE,
Research Student	Yousuke MURAKAMI,	
Resident	Naoki KIMURA, Tadashi HOSOYA, Tomoko TAKIZAWA, Yoko NAKAZATO, Yusuke MATSUO,	Hisanori HASEGAWA, Hayato YAMAZAKI, Kenshi TAKENAKA, Shin FUKUDA, Waka YOKOYAMA

### 2. Purpose of Education

We have provided medical students and graduates with the opportunity to obtain the ability to identify important clinical problems and to solve them by clinical reasoning through their active participation into the diagnosis and management of various rheumatic diseases.

### 3. Research Subjects

Following studies have been extensively carried out in our laboratory with various biochemical, immunological, molecular biological and statistical techniques:

- 1) Development of new therapeutics for the treatment of rheumatoid arthritis using cell cycle regulators.
- 2) Investigation of mechanism and development of new therapeutics for polymyositis.
- 3) The pathological role of chemokines/chemokine receptors in autoimmune diseases, including rheumatoid arthritis, polymyositis and scleroderma, for understanding their mechanisms and development of new therapeutics.
- 4) Investigation of role of BAFF/BLyS and Toll-like receptor in SLE.
- 5) Establishment of evidence-based treatment of rheumatic diseases.

### 4. Clinical Services

We have provided care to a large number of patients with diverse rheumatic diseases with 24,033 clinic visits and 299 hospital admissions in 2009. We have aimed to practice evidence-based medicine and to provide care that is in accordance with the global standard. We have contributed to the development of potential new drugs and treatments through participation into industry- as well as investigator-initiated clinical trials for chemical and biological agents. We have also contributed to the refinement of the care of rheumatoid arthritis patients through the conduct of various pharmacovigilance studies.

### 5. Publications

#### Original Article

1. Miyasaka N. Adalimumab for the treatment of rheumatoid arthritis. *Expert Rev. Clin. Immunol.* 5(1):19-26, 2009
2. Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis a placebo-controlled double-blind multicenter study. *Mod. Rheumatol.* 19:606-615, 2009
3. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T. Study of Active controlled Tocilizumab monotherapy for Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate

- (SATORI) : significantly reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. *Mod. Rheumatol.* 19:12-19, 2009
4. Hashimoto J, Garner P, D. van der Heijde, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, Nishimoto N. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict progression of joint destruction in patients with rheumatoid arthritis treated with disease modifying anti-rheumatic drugs. *Mod. Rheumatol.* 19:273-282, 2009
  5. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, Sekiguchi N, Inoo M, Onishi I, Ohashi H, Amamoto F, Miyata M, Ohtsubo H, Hiramatsu K, Iwamoto M, Minota S, Matsuoka N, Kageyama G, Imaizumi K, Tokuda H, Okochi Y, Kudo K, Tanaka Y, Takeuchi T, Miyasaka N. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab : a retrospective review and case-control study of 21 patients. *Arthritis & Rheum.* 61(3):305-312, 2009
  6. Nanki T, Takada K, Komano Y, Morio T, Kanegane H, Nakajima A, Lipsky PE, Miyasaka N. Chemokine receptor expression and functional effects of chemokines on B cells: Implication in the pathogenesis of rheumatoid arthritis. *Arthritis Res. Ther.* 11:R149, 2009.
  7. Watanabe K, Nanki T, Sugihara T, Miyasaka N. A case of polyarteritis nodosa with periurethral aseptic abscesses and testicular lesions. *Clin. Exp. Rheumatol.* 26:1113-1115, 2009
  8. Nii T, Kubota T, Nanki T, Komano Y, Harigai M, Kohsaka H, Hirose W, Nagasaka K, Sakurai T, Miyasaka N. Reevaluation of antibody titers 1 year after influenza vaccination in patients with rheumatoid arthritis receiving TNF blockers. *Mod. Rheumatol.* 19:216-218, 2009
  9. Nonomura Y, Mizoguchi F, Suzuki A, Nanki T, Kato H, Miyasaka N, Kohsaka H. Hypoxia-induced abrogation of contact-dependent inhibition of rheumatoid arthritis synovial fibroblast proliferation. *J. Rheumatol.* 36(4):698-705, 2009
  10. Nonomura Y, Miyabe Y, Tanaka M, Tsubata R, Nanki T, Harigai M and Miyasaka N. Prominent splenic microcalcification in patient with systemic lupus erythematosus complicated with antiphospholipid syndrome. *J Clin Rheumatol.* (in press).
  11. Kishi J, Nanki T, Watanabe K, Takamura A, Miyasaka N. A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. *Rheumatol.* 48:447-448, 2009
  12. Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, Saito T, Yamamura M, Matsubara T, Miyasaka N. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. *Mod. Rheumatol.* 19:351-357, 2009
  13. Kubota T, Fukuya Y, Hashimoto R, Kanda T, Suzuki H, Okamura Y, Nanki T, Miyasaka N, Umezawa K. Possible involvement of chemokine-induced platelet activation in thrombophilic diathesis of antiphospholipid syndrome. *Ann. N.Y. Acad. Sci.* 1173:137-145, 2009
  14. Ohyanagi N, Ishido M, Suzuki F, Kaneko K, Kubota T, Miyasaka N, Nanki T. Retinoid ameliorates experimental autoimmune myositis, with modulation of Th cell differentiation and antibody production in vivo. *Arthritis Rheum.* 60:3118-3127, 2009.
  15. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. *Ann. Rheum. Dis.* 68:1580-1584, 2009
  16. Takahashi N, Matsumoto K, Saito H, Nanki T, Miyasaka N, Kobata T, Azuma M, Lee S-K, Nizutani S, Morio T. Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. *J. Immunol.* 182(9):5515-5527, 2009
  17. Ochi S, Nanki T, Kaneko H, Honne K, Miyazaki Y, Komano Y, Miyasaka N. Successful treatment of ankylosing spondylitis coexisting with pulmonary sarcoidosis by infliximab. *Clin. Exp. Rheumatol.* 27:698-699, 2009.
  18. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. *Mod. Rheumatol.* 19(5):478-87, 2009
  19. Murakami Y, Akahoshi T, Aoki N, Toyomoto M, Miyasaka N, Kohsaka H. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. *Arthritis Rheum.* 60(6):1615-1623, 2009
  20. Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of IL-6 blockade on a murine model of polymyositis that does not require IL-17A. *Arthritis Rheum.* 60 (8):2505-2512, 2009
  21. Sato A, Watanabe K, Kaneko K, Murakami Y, Ishido M, Miyasaka N, Nanki T. The effect of synthetic retinoid,

- Am80, on T helper cell development and antibody production in murine collagen-induced arthritis. *Mod Rheumatol*. 2009 Dec 29. [Epub ahead of print]
22. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. *J. Rheumatol*. 36(5):898-906, 2009
  23. Saita Y, Nakamura T, Mizoguchi F, Nakashima K, Hemmi H, Hayata T, Ezura Y, Kurosawa H, Kato S, Noda M. Combinatory Effects of Androgen Receptor Deficiency and Hind Limb Unloading on Bone. *Horm Metab Res*. 41:822-8, 2009
  24. Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T, Nakashima K, Inagami T, Ezura Y, Noda M. Angiotensin II type 2 receptor blockade increases bone mass. *J Biol Chem*. 284:4857-64, 2009.
  25. Piao J, Kamimura Y, Iwai H, Cao Y, Kikuchi K, Hashiguchi M, Masunaga T, Jiang H, Tamura K, Sakaguchi S, Azuma M. Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours. *Immunology*. Aug;127(4):489-99, 2009
  26. Su LL, Iwai H, Lin JT, Fathman CG. The transmembrane E3 ligase, GRAIL ubiquitinates and degrades CD83 on CD4 T cells. *J. Immunol*. Jul;183(1):438-44, 2009
  27. Kamimura Y, Iwai H, Piao J, Hashiguchi M, Azuma M. The glucocorticoid-induced TNF receptor-related protein (GITR)-GITR ligand pathway acts as a mediator of cutaneous dendritic cell migration and promotes T cell-mediated acquired immunity. *J. Immunol*. Mar;182(5):2708-16, 2009
  28. Farrell S, K. Takada, E.G. Armstrong, Y. Tanaka, H.T. Aretz, "Reform of a traditional clinical curriculum in Japan: Experiences at Tokyo Medical and Dental University". *Medical Teacher*, 31(10): 947-9, 2009
  29. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, Fleisher TA, Wilson M, Goldbach-Mansky R, Lipsky PE. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. *Arthritis Res. Ther*. 11:R84, 2009.
  30. Hirose W, Nishikawa K, Hirose M, Nanki T, Sugimoto H. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging. *Mod. Rheumatol*. 19:20-26, 2009.
  31. Kozako, T., Fukada, K., Hirata, S., White, Y., Harao, M., Nishimura, Y., Kino, Y., Soeda, S., Shimeno, H., Lemonnier, F., Sonoda, S., and Arima, N. Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia. *Mol Immunol*, 47: 606-613, 2009
  32. Inoue, M., Senju, S., Hirata, S., Irie, A., Baba, H. and Nishimura, Y. An in vivo model of priming of antigen-specific human CTL by Mo-DC in NOD/Shi-scid IL2rgamma(null) (NOG) mice. *Immunol Lett* 126(1-2): 67-72, 2009
  33. Fukushima, S., Hirata, S., Motomura, Y., Fukuma, D., Matsunaga, Y., Ikuta, Y., Ikeda, T., Kageshita, T., Ihn, H., Nishimura, Y. and Senju, S. Multiple Antigen-targeted Immunotherapy With alpha-Galactosylceramide-loaded and Genetically Engineered Dendritic Cells Derived From Embryonic Stem Cells. *J Immunother* 32(3): 219-231, 2009
  34. Ikuta, Y. \*, Hayashida, Y. \*, Hirata, S., Irie, A., Senju, S., Kubo, T., Nakatsura, T., Monji, M., Sasaki, Y., Baba, H., and Nishimura, Y. (\*equal contribution) Identification of the H2-Kd-restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice. *Cancer Sci* 100(1): 132-7, 2009